Market Overview

Morgan Stanley Hopes for Some Retail Therapy for Humana

Share:
Related HUM
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
Watch These 3 Huge Put Purchases In Friday Trade
DOJ challenges Aetna-Humana deal (Seeking Alpha)

In a report published Thursday, Morgan Stanley analyst Andrew Schenker reiterated an Equal-Weight rating on Humana (NYSE: HUM).

In the report, Morgan Stanley noted, “HUM maintained its 2014 EPS outlook of $7.25 to $7.75, but increased its Medicare Advantage, Part D, and commercial individual enrollment outlook on the heels of 4Q. We have lowered our FY14 EPS by $0.05 to $7.70, which reflects higher revenue from new lives, but a lower overall pre-tax margin.”

Humana closed on Wednesday at $95.71.

Latest Ratings for HUM

DateFirmActionFromTo
Nov 2016Credit SuisseUpgradesNeutralOutperform
Nov 2016JP MorganUpgradesNeutralOverweight
Sep 2016Evercore ISI GroupInitiates Coverage onBuy

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!